Investor Presentaiton

Robust Pipeline in Both Oncology and Non-oncology with 25 Valuable Assets Across Diversified Clinical Stages • • • . TYVYTⓇ (sintilimab injection) BYVASDAⓇ (bevacizumab injection) SULINNOⓇ (adalimumab injection) HALPRYZAⓇ (rituximab injection) PemazyreⓇ (pemigatinib) 1 IBI-348 (BCR-ABL/KIT), NDA accepted by NMPA in 1H 2020 for treatment of drug- resistant CML Co-commercialization with Ascentage Pharma in China • 亞盛醫藥 Ascentage Pharma IBI-376 (PI3KS) r/r FL, pivotal Phase 2 ongoing • IBI-306 (PCSK9) • HeFH, met Phase 3 primary endpoints IBI-310 (CTLA-4) Combo with TYVYT in pivotal trials for multiple indications including HCC, ovarian cancer and melanoma IBI-326 (BCMA CAR-T) r/r MM, pivotal Phase 2 ongoing IBI-344 (ROS1/NTRK) NSCLC, pivotal Phase 2 ongoing • High potential IO targets: CD47 (IBI-188, IBI-322) LAG-3 (IBI-110, IBI-323) TIGIT (IBI-939, IBI-321) Bispecific candidates: IBI-319 (PD-1/CD137) IBI-315 (PD-1/Her2) Non-oncology candidates: IBI-362 (OXM3) - IBI-302 (VEGF/C-protein) IBI-112 (IL-23 p19) 5 assets approved 1 NDA under TITT NMPA review இ 5 assets at late stage Oncology:20 assets spanning in mAb, bispecific antibody, cell therapy, and small molecule ur TS 14 assets at Phase 1 or 2 Non-oncology: 5 assets spanning in autoimmune, ophthalmology, 4.8 ER NOTHERAPY Note: 1) Pemigatinib (IBI-375) has been approved in Taiwan market in June 2021, NDA submission accepted by NMPA in Jul 2021 Innovent Confidential Copyright©2021 Innovent Biologics metabolic 8

View entire presentation